FDA Approves Darzalex (daratumumab) Split-Dosing Regimen

Horsham, PA, February 12, 2019– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved a split-dosing regimen for Darzalex® (daratumumab), providing...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news